Daiichi Sankyo Chemical Pharma Co., Ltd. – FDA 483, Jul 1, 2021
This 483 report for Daiichi Sankyo Chemical Pharma Co., Ltd. in Gunma, Japan, details significant deficiencies in manufacturing process control, quality unit separation, deviation and CAPA management, facility cleaning procedures, and pest control. The observations indicate a lack of adherence to established procedures, ineffective corrective actions, and potential risks to product quality and facility integrity. The inspection identified repeated issues, highlighting systemic problems in quality oversight and operational compliance.
ID · 7ce9fe39-58c7-4948-867e-0ea069c003d8
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.